Associated Press - December 2, 2004
Jeff Donn

BOSTON - In a sharp pivot, many medical authorities are questioning the fundamental safety guarantees for American drugs, threatening to dull the national appetite that has demanded and devoured pharmaceuticals at a faster clip.

In a challenge unthinkable even two months ago, Dr. Catherine DeAngelis, editor of the Journal of the American Medical Association, compares the drug safety system to a dangerous building:

'This building is on very shaky ground. Would I condemn it? No, but I would tell people, `You go in at your own risk.' "

In recent months, troubling news about several high-profile drugs has sapped confidence in the system for flushing out dangerous medicines and assuring the supply of safe ones. Worries abound over the safety of antidepressants, the recall of the pain reliever Vioxx, and a winter with rationed flu vaccine.

Such intense outcries over safety have rarely been heard since the 1960s, when the European thalidomide scandal of deformed babies motivated the United States to fashion a more protective federal Food and Drug Administration.

Since the late '80s, Americans have mostly been begging for faster approval of presumed lifesaving drugs for such diseases as AIDS and cancer. Lately, they are wondering if medicines -- pumped out by a $200 billion annual industrial powerhouse -- are arriving too fast and doing too much harm.

During recent interviews with The Associated Press, experts within and outside government responded with some jarring answers: No drug is ever fully safe, any more than a drive down the highway. The safety net is not designed to catch rare side effects until drugs reach the market. By then, regulators are often powerless to spot mistakes quickly and reluctant to jump on them, according to many drug authorities.

Dr. Jerry Avorn, a Harvard Medical School expert who wrote a book on the drug industry, says recent revelations about the FDA suggest "a culture of denial" about dangerous side effects, especially once a drug is on the market. Some authorities contend that FDA's post-marketing safety monitors need more independence from the unit that evaluates drugs for approval.

Dr. Steven Galson, acting director of FDA's drug operation, says the agency forces companies to overcome "a high hurdle" to demonstrate drug safety. However, he also says that "the group that approves new drugs does invest a lot of time and energy, and it is a very legitimate question to ask if they can [properly] look at new information that comes up."

Nearly everyone believes repair is possible, but few predict quick sweeping action.

"The system itself is completely broken," says Dr. David Graham, a senior safety scientist at the FDA who has begun speaking outside the agency's chain of command. "The system is incapable of preventing another Vioxx."

Many analysts trace purported safety failings to 1992, when Congress adopted industry-paid user fees to pay for faster FDA reviews. Waits for standard drug approval have typically been cut by more than half, to under one year, government data show.

However, critics say the funding makes the industry, not the public, the agency's master. And many members of FDA advisory panels have ties to drug companies.

041202
AP041213

Copyright © 2004 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .